HAMILTON, ONTARIO – At the 2018 LSO Annual Awards Presentation event, Fusion Pharmaceuticals was awarded “Life Sciences Company of the Year.” The award recognizes Fusion as an outstanding company which contributed to the success of Ontario’s life sciences sector.
John Valliant, CEO and Founder of Fusion Pharmaceuticals, accepted the award on behalf of the company. “It’s an honor to be recognized by Life Sciences Ontario (LSO) and we feel privileged to be a part of the Life Sciences community in Ontario”, said Dr. Valliant. “Fusion was launched with the support of an international syndicate of investors and a world-class team to develop and advance innovative cancer therapies. This is an exciting year for Fusion as a key goal is to conduct a clinical trial across the US and Canada on our lead program FPX-01.
At the award ceremony, Fusion was recognized for its proprietary technology, growing pipeline, rapid progress in moving innovative therapeutics to the clinic, and the potential of FPX-01 to treat a wide range of cancer types.
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit www.fusionpharma.com or contact email@example.com.